Abbott’s Metabolic Health Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing

“We’re so steeped in scientific and medical expertise that we never really learned how to talk to or with regular people,” says Abbott CEO Robert Ford.

Lingo, based on Abbott’s FreeStyle Libre diabetes management technology but targeted to the consumer market, works with a companion app to identify user habits that negatively impact their health and guide them in modifying behaviors accordingly. Olivier Ropars, division VP of Lingo Biowearables, discusses the company's recent UK launch and future plans.

• Source: Medtech Insight

It’s been two months since Abbott’s new biosensing wearable Lingo, designed to enable consumers to monitor their metabolic health, made its debut in the United Kingdom. And thus far, the reception in that test market has been “extremely positive,” Olivier Ropars, division vice president of Abbott’s Lingo Biowearables told Medtech Insight at the HLTH conference last week.

More from Strategy

People On The Move: Appointments At PAGB, Activ’Inside, EMA

 
• By 

Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.

People On The Move: Appointments At GSCF, Kenvue, Barentz

 
• By 

A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.

Galenica OTC Goes From Strength To Strength At Home And Abroad

 
• By 

Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.

Alliance Pharma Takeover Wins Shareholder Backing After Increased Offer

 
• By 

Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.

More from Business

Alliance Pharma Takeover Wins Shareholder Backing After Increased Offer

 
• By 

Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.

New Product Launches Ensured Growth For Stada CHC In 2024

 
• By 

Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.

Bayer Consumer Health Outlook Accelerated By ‘Dynamic’ Cuts To Staff Layers, Efficiency Boost

 

Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."